LOGICBIO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 15th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 15th, 2021 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered as of the last date set forth on the signature page below by and between LogicBio Therapeutics, Inc. (the “Company”) and Cecilia Jones (“Executive”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT LOGICBIO THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 5 TO AMENDED AND RESTATED...Exclusive (Equity) Agreement • March 15th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 15th, 2021 Company Industry JurisdictionTHIS AMENDMENT NO. 5 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 5”) is made as of October 30, 2020 (“Amendment No. 5 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, and amended again by that certain Amendment No. 4 dated April 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreem